NextPlat (NASDAQ: NXPL, NXPLW) announced that its wholly owned pharmacy subsidiary, PharmcoRx, plans to introduce automated prescription dispensing kiosks from VendRx at select customer clinics and health care facilities. The kiosks will allow patients to obtain prescribed medications onsite following appointments and consultation with a PharmcoRx pharmacist, reducing the need for separate pharmacy visits. Initial installations are planned for the fourth quarter of 2026, with broader deployment expected throughout 2027. The initiative is designed to improve medication access and adherence while expanding PharmcoRx’s prescription services and relationships with health care providers.
VendRx reports approximately 80% formulary coverage per deployment and more than 90,000 successful prescription dispenses since inception, with no wrong-medication releases reported through Oct. 19, 2026, according to its internal records. NextPlat said the kiosks could help address gaps in pharmacy access, particularly in underserved communities, while allowing clinics to offer prescription dispensing without additional staffing or onsite pharmacy construction. The company expects the program to create an additional prescription channel for PharmcoRx and support its expansion through independent clinics and health care providers.
To view the full press release, visit https://ibn.fm/dIWEa
About NextPlat Corp.
NextPlat is a global consumer products and services company providing healthcare and technology solutions through e-Commerce and retail channels worldwide. Through acquisitions, joint ventures, and collaborations, the Company seeks to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-Commerce presence and revenue. NextPlat currently operates an e-Commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care.
NOTE TO INVESTORS: The latest news and updates relating to NXPL are available in the company’s newsroom at https://ibn.fm/NXPL
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN